Medipower in the first quarter: assets arrived faster than FFO

Medipower did not report a weak quarter in the usual operating sense. It reported a transition quarter in which the balance sheet moved faster than the income statement. NOI rose about 15% to $7.0 million, occupancy increased to 95%, and the portfolio expanded by 13 assets acquired in March, but shareholder AFFO fell to $1.9 million because the debt is already in the numbers while the new properties barely had time to contribute. That is the main read: 2026 will no longer be judged by whether the deals close, but by whether representative NOI turns into shareholder FFO after debt, minority interests, and the partnership with Phoenix. Management points to representative annual FFO of $19 million to $21 million after the acquisitions are completed, compared with a current quarterly pace that is far below that level. The bottleneck is not weak tenant demand. It is timing, financing, and value capture. Until the next quarters show the full contribution of the new assets, the rise in non-current assets and debt is harder evidence than the improvement in profitability. The near-term test is completion of the remaining ten assets in the larger portfolio, normalization of the debt-to-NOI ratio once the assets operate for a full quarter, and proof that growth remains accessible to shareholders rather than only to the consolidated balance sheet.

The New Assets Have Not Worked Long Enough Yet

Medipower is a U.S. commercial income-producing real estate company. Through AM West it holds 31 properties in Pennsylvania, New York, Massachusetts, New Jersey, Connecticut, South Carolina, Virginia, and Georgia, with about 295 thousand square meters of leasable area. The portfolio includes about 450 commercial tenants, and average occupancy at the end of March 2026 was 95%, compared with 94% a year earlier.

The economic machine here is a mix of assets and leverage. The existing operation produces relatively stable NOI, but value creation in 2026 depends on large acquisitions, a partner that funds part of the equity, and the ability to increase shareholder FFO faster than debt. This is not only a development story or a one-off fair-value story. It is a company trying to convert a larger property base into recurring cash flow while preserving reasonable leverage and access to financing.

The tenant mix explains why the portfolio looks relatively resilient: supermarkets account for about 40% of revenue, food and beverages for about 17%, service providers for about 16%, and discount stores for about 6%. Only 3% of revenue comes from leases expiring in 2026. Still, concentration around supermarket-anchored open-air centers does not remove the financing test. Even a stable asset can weigh on shareholders if it enters the balance sheet with debt before it has time to contribute to NOI and FFO.

The important number in the quarter is not the $1.4 million net loss. It is the gap between assets already acquired and assets that have not yet worked long enough inside the results. The first six assets from the 16-property portfolio were acquired during March, so they contributed less than one month to NOI. The additional seven-property portfolio closed on March 31, so it contributed no NOI at all to the first quarter.

That explains why NOI rose to $7.0 million from $6.1 million in the comparable quarter, while shareholder AFFO fell to $1.9 million from $2.7 million. The debt issued and taken to fund growth has already affected finance expenses. The full operating contribution will arrive later only if the assets actually produce at the pace presented.

This gap makes the quarter less an operating test and more a timing test. The 16-property portfolio has representative annual NOI of about $19.9 million, total occupancy of about 96%, and an average lease term of about five years. The seven-property portfolio has representative annual NOI of about $7.5 million, occupancy of about 99.6%, and an average lease term of about five years. If those numbers enter results without erosion, the first quarter will later look like a reasonable transition quarter. If not, the market will learn that growth was more expensive than the representative number implied.

The Balance Sheet Already Shows The Price

The other side of the acquisitions is already clearer. Non-current assets rose to $662.2 million at the end of March, from $468.7 million at the end of 2025. Loans from financial institutions rose to about $371 million, at an average annual rate of 4.36%, in addition to the shekel bonds. Consolidated cash fell to $34.7 million from $73.1 million at the end of 2025.

The all-in cash picture shows that the quarter was built mainly by moving money into assets and subsidiaries, not by internal excess cash. Operating cash flow was $5.2 million, but investing activity used $197.4 million, mainly for acquisitions, while financing activity brought in $153.8 million. At the parent level, cash fell to $2.8 million after $60 million of loans were provided to investees. The issue is therefore not only whether there are enough assets, but how quickly cash pushed down the structure starts moving back up through management fees, interest, loan repayments, and distributions.

The covenant tells the same story. The company complies with the covenants on its bonds and loans, but net financial debt to NOI reached 15.3, above the 15 threshold that activates a rate step-up on Series B bonds. The direct cost is negligible, about $6 thousand per quarter, but the signal is not negligible: debt rose before the NOI of assets acquired on March 31 entered the calculation. Management notes that if the acquired assets had generated full-quarter NOI, the ratio would have been 14.0. That does not solve the test, but it defines it precisely.

The partnership with Phoenix is the central growth engine of the year, but it is also the reason consolidated NOI needs to be read carefully. The institutional partner holds 49% of the limited-partner rights in the portfolio and contributes significant equity to the deals. That reduces the amount of equity Medipower has to bring by itself and lets the company buy a much larger portfolio than would likely fit a narrower standalone balance sheet.

Still, this is not free capital. Non-controlling interests rose to $57.8 million at the end of March, from $21.2 million at the end of 2025. The FFO calculation already shows the cut: regulatory-method FFO was $1.77 million, but after the share of non-controlling interests, $1.19 million was left for shareholders. After management adjustments, shareholder AFFO was $1.93 million.

This is where prior coverage receives its first proof point. Earlier Deep TASE work on Medipower, including the shareholder NOI bridge and the return-after-financing test, highlighted whether new growth would reach shareholders or remain mostly at the asset level. The first quarter does not decide the issue, but it already shows the direction: the balance sheet grows immediately, minority interests grow immediately, and shareholder FFO has to catch up in the next quarters.

2026 Is A Proof Year, Not A Technical Closing Year

Management estimates that after the acquisitions are completed, representative annual FFO will be $19 million to $21 million. Against quarterly AFFO of $1.9 million, that target requires a clear change in pace over the next few quarters. The positive explanation is straightforward: 13 assets entered too late to affect the first quarter, so the current pace is not representative. That explanation will remain convincing only if the second and third quarters show an actual step-up, not just more balance-sheet growth.

The first trigger is completion of the remaining 10 assets from the 16-property portfolio by the end of the second quarter. The market will not look only for a closing notice. It will also look at debt terms, loan-to-value, and financing cost. The first five assets in the portfolio were financed through a seven-year non-recourse loan at a fixed 5.33% rate, with interest-only payments for the first three years. The sixth asset came with a loan at 3.38%. If the remaining assets close on weaker terms, representative NOI will look less impressive after financing.

The second trigger is repair of the debt-to-NOI ratio after the assets operate for a full period. The cost of the Series B rate step-up is small, but a 15.3 ratio against a 15 threshold sharpens what the market will test: whether the breach was only a balance-sheet-date distortion, or whether the company is pushing leverage faster than proven NOI.

The third trigger is currency. After the balance-sheet date and near publication, the U.S. dollar fell about 8% against the shekel compared with March 31, 2026, and the company expects a translation loss of about $8.5 million to be recorded in profit or loss and other comprehensive income. That does not change the performance of the U.S. assets, but it can blur the bottom line in the next reports and create noise around reported equity.

Conclusion

Medipower's first quarter leaves a mixed but useful conclusion: the operating business is not broken, and the new assets look meaningful on paper, but shareholders have not yet received proof that this engine works for them. NOI grew, occupancy rose, and the company completed large acquisitions. At the same time, shareholder AFFO fell, the balance sheet became more levered, parent-level cash fell sharply, and minority interests increased.

The current conclusion is that 2026 should be read as a proof year. If the 13 assets acquired in March, plus the remaining 10 assets in the larger portfolio, start producing full NOI, the debt-to-NOI ratio falls back below the rate step-up threshold, and shareholder AFFO moves toward management's representative annual FFO range, the first quarter will look like a reasonable timing distortion. If that does not happen, this quarter will be an early sign that growth is buying asset size faster than shareholder earnings. That is what will determine the market read over the next quarters.